MA43960A - Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 - Google Patents
Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1Info
- Publication number
- MA43960A MA43960A MA043960A MA43960A MA43960A MA 43960 A MA43960 A MA 43960A MA 043960 A MA043960 A MA 043960A MA 43960 A MA43960 A MA 43960A MA 43960 A MA43960 A MA 43960A
- Authority
- MA
- Morocco
- Prior art keywords
- hiv
- inhibitors
- compounds
- modified triterpenoids
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
- C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/52—Ortho- or ortho- and peri-condensed systems containing five condensed rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne des composés ayant des propriétés thérapeutiques et bioactives, leurs compositions pharmaceutiques et leurs procédés d'utilisation. L'invention concerne, en particulier, des dérivés de l'acide bétulinique ayant une activité antivirale unique, qui sont utilisés comme inhibiteurs de maturation du vih, tels que représentés par des composés de formule i : ces composés s'avèrent utiles dans le traitement du vih et du sida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291298P | 2016-02-04 | 2016-02-04 | |
| PCT/IB2017/050568 WO2017134596A1 (fr) | 2016-02-04 | 2017-02-02 | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA43960A true MA43960A (fr) | 2018-12-12 |
| MA43960B1 MA43960B1 (fr) | 2021-02-26 |
Family
ID=57995251
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43960A MA43960B1 (fr) | 2016-02-04 | 2017-02-02 | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 |
| MA053358A MA53358A (fr) | 2016-02-04 | 2017-02-02 | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053358A MA53358A (fr) | 2016-02-04 | 2017-02-02 | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US10421774B2 (fr) |
| EP (2) | EP3831839B1 (fr) |
| JP (1) | JP6735837B2 (fr) |
| KR (1) | KR102795662B1 (fr) |
| CN (1) | CN109153700B (fr) |
| AR (1) | AR107512A1 (fr) |
| AU (1) | AU2017215529B2 (fr) |
| BR (1) | BR112018015629B1 (fr) |
| CA (1) | CA3013417C (fr) |
| CL (1) | CL2018002084A1 (fr) |
| CO (1) | CO2018008157A2 (fr) |
| CR (1) | CR20180387A (fr) |
| CY (1) | CY1124353T1 (fr) |
| DK (1) | DK3411381T3 (fr) |
| DO (1) | DOP2018000174A (fr) |
| EA (1) | EA036211B1 (fr) |
| ES (2) | ES2862325T3 (fr) |
| HR (1) | HRP20210502T1 (fr) |
| HU (1) | HUE054337T2 (fr) |
| IL (1) | IL260741B (fr) |
| JO (1) | JOP20170029B1 (fr) |
| LT (1) | LT3411381T (fr) |
| MA (2) | MA43960B1 (fr) |
| MD (1) | MD3411381T2 (fr) |
| MX (1) | MX375118B (fr) |
| MY (1) | MY199668A (fr) |
| PE (1) | PE20181355A1 (fr) |
| PL (1) | PL3411381T3 (fr) |
| PT (1) | PT3411381T (fr) |
| RS (1) | RS61746B1 (fr) |
| RU (1) | RU2716502C2 (fr) |
| SG (1) | SG11201806388XA (fr) |
| SI (1) | SI3411381T1 (fr) |
| SM (1) | SMT202100210T1 (fr) |
| TW (1) | TWI719126B (fr) |
| UA (1) | UA123867C2 (fr) |
| UY (1) | UY37109A (fr) |
| WO (1) | WO2017134596A1 (fr) |
| ZA (1) | ZA201805044B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR107512A1 (es) * | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| ES2970042T3 (es) | 2018-04-24 | 2024-05-24 | Viiv Healthcare Uk No 5 Ltd | Compuestos con actividad inhibidora de la maduración del VIH |
| JP7703538B2 (ja) | 2019-12-09 | 2025-07-07 | ヴィーブ、ヘルスケア、カンパニー | カボテグラビルを含んでなる医薬組成物 |
| WO2024089216A1 (fr) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Nouveaux composés hétéroaryl-carboxamides contenant du soufre |
| WO2025037232A1 (fr) | 2023-08-11 | 2025-02-20 | ViiV Healthcare UK (No.4) Limited | Forme de sel de tosylate d'un inhibiteur de maturation pour le traitement du vih |
| AU2024353051A1 (en) | 2023-09-27 | 2026-03-12 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical compositions |
| AU2023466962A1 (en) | 2023-09-27 | 2026-03-12 | ViiV Healthcare UK (No.3) Limited | Pharmaceutical composition of cabotegravir |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5679828A (en) | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| GB0301227D0 (en) | 2003-01-20 | 2003-02-19 | Keen Group Ltd | Seating apparatus |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| BRPI0508854A (pt) | 2004-03-17 | 2007-08-28 | Panacos Pharmaceuticals Inc | sais farmacêuticos de ácido-3-o-(3',3'-dimetilsuccinil) betulìnico |
| TW200628161A (en) | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| WO2008115281A2 (fr) | 2006-10-16 | 2008-09-25 | Myriad Genetics, Inc. | Composés de traitement d'infections virales |
| CA2714049A1 (fr) | 2008-02-14 | 2009-08-20 | Virochem Pharma Inc. | Nouveaux derives de 17ss-lupane |
| US9067966B2 (en) | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
| FR2956034B1 (fr) | 2010-02-09 | 2012-02-10 | Thales Sa | Dispositif d'entrainement pour des joueurs de rugby |
| RS54239B1 (sr) | 2010-06-04 | 2015-12-31 | Bristol-Myers Squibb Company | C-28 amidi modifikovanih derivata c-3 betulinske kiseline kao inhibitori sazrevanja hiv-a |
| US8754068B2 (en) | 2010-06-04 | 2014-06-17 | Bristol-Myers Squibb Company | Modified C-3 betulinic acid derivatives as HIV maturation inhibitors |
| DE102010017786A1 (de) | 2010-07-07 | 2012-01-12 | Continental Reifen Deutschland Gmbh | Elastomerprodukt, enthaltend ein linienförmiges, textiles Gebilde zur Verstärkung |
| HUE026371T2 (en) | 2011-01-31 | 2016-05-30 | Bristol Myers Squibb Co | C-28 amines from modified C-3 betulinic acid derivatives as anti-HIV matrices |
| US8846647B2 (en) * | 2011-01-31 | 2014-09-30 | Bristol-Myers Squibb Company | C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity |
| BR112014014046A2 (pt) * | 2011-12-14 | 2017-06-13 | Glaxosmithkline Llc | composto, composição, e, método para tratar hiv |
| US8906889B2 (en) * | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
| US8889854B2 (en) | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
| CA2894126A1 (fr) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| US9378035B2 (en) | 2012-12-28 | 2016-06-28 | Commvault Systems, Inc. | Systems and methods for repurposing virtual machines |
| JP6186010B2 (ja) * | 2013-02-06 | 2017-08-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｉｖ成熟阻害活性を有するｃ−１９修飾トリテルペノイド類 |
| KR20150121712A (ko) * | 2013-02-25 | 2015-10-29 | 브리스톨-마이어스 스큅 컴퍼니 | Hiv의 치료에 유용한 c-3 알킬 및 알케닐 개질된 베툴린산 유도체 |
| CN104877015B (zh) * | 2014-02-28 | 2019-02-01 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种三萜-多肽缀合物、其药物组合物及用途 |
| UY36070A (es) | 2014-04-11 | 2015-10-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Triterpenoides con actividad inhibidora de la maduración de hiv |
| MA40886B1 (fr) | 2015-02-09 | 2020-03-31 | Hetero Research Foundation | Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih |
| PL3411358T3 (pl) | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| AR107512A1 (es) * | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
-
2017
- 2017-02-01 AR ARP170100255A patent/AR107512A1/es active IP Right Grant
- 2017-02-02 UA UAA201808249A patent/UA123867C2/uk unknown
- 2017-02-02 AU AU2017215529A patent/AU2017215529B2/en active Active
- 2017-02-02 MD MDE20181181T patent/MD3411381T2/ro unknown
- 2017-02-02 JO JOP/2017/0029A patent/JOP20170029B1/ar active
- 2017-02-02 WO PCT/IB2017/050568 patent/WO2017134596A1/fr not_active Ceased
- 2017-02-02 JP JP2018540806A patent/JP6735837B2/ja active Active
- 2017-02-02 PL PL17704093T patent/PL3411381T3/pl unknown
- 2017-02-02 KR KR1020187025343A patent/KR102795662B1/ko active Active
- 2017-02-02 SG SG11201806388XA patent/SG11201806388XA/en unknown
- 2017-02-02 EP EP21152161.2A patent/EP3831839B1/fr active Active
- 2017-02-02 ES ES17704093T patent/ES2862325T3/es active Active
- 2017-02-02 RS RS20210450A patent/RS61746B1/sr unknown
- 2017-02-02 CN CN201780018790.8A patent/CN109153700B/zh active Active
- 2017-02-02 TW TW106103410A patent/TWI719126B/zh active
- 2017-02-02 CR CR20180387A patent/CR20180387A/es unknown
- 2017-02-02 PE PE2018001378A patent/PE20181355A1/es unknown
- 2017-02-02 HU HUE17704093A patent/HUE054337T2/hu unknown
- 2017-02-02 CA CA3013417A patent/CA3013417C/fr active Active
- 2017-02-02 US US16/071,925 patent/US10421774B2/en active Active
- 2017-02-02 SM SM20210210T patent/SMT202100210T1/it unknown
- 2017-02-02 MX MX2018009514A patent/MX375118B/es active IP Right Grant
- 2017-02-02 SI SI201730647T patent/SI3411381T1/sl unknown
- 2017-02-02 BR BR112018015629-9A patent/BR112018015629B1/pt active IP Right Grant
- 2017-02-02 PT PT177040938T patent/PT3411381T/pt unknown
- 2017-02-02 UY UY0001037109A patent/UY37109A/es not_active Application Discontinuation
- 2017-02-02 EP EP17704093.8A patent/EP3411381B1/fr active Active
- 2017-02-02 RU RU2018130181A patent/RU2716502C2/ru active
- 2017-02-02 LT LTEP17704093.8T patent/LT3411381T/lt unknown
- 2017-02-02 MA MA43960A patent/MA43960B1/fr unknown
- 2017-02-02 HR HRP20210502TT patent/HRP20210502T1/hr unknown
- 2017-02-02 ES ES21152161T patent/ES2957767T3/es active Active
- 2017-02-02 MY MYPI2018702694A patent/MY199668A/en unknown
- 2017-02-02 EA EA201891649A patent/EA036211B1/ru unknown
- 2017-02-02 DK DK17704093.8T patent/DK3411381T3/da active
- 2017-02-02 MA MA053358A patent/MA53358A/fr unknown
-
2018
- 2018-07-23 IL IL260741A patent/IL260741B/en active IP Right Grant
- 2018-07-26 ZA ZA2018/05044A patent/ZA201805044B/en unknown
- 2018-07-30 DO DO2018000174A patent/DOP2018000174A/es unknown
- 2018-07-31 CO CONC2018/0008157A patent/CO2018008157A2/es unknown
- 2018-08-02 CL CL2018002084A patent/CL2018002084A1/es unknown
-
2019
- 2019-08-07 US US16/534,208 patent/US11084845B2/en active Active
-
2021
- 2021-04-08 CY CY20211100303T patent/CY1124353T1/el unknown
- 2021-06-09 US US17/342,941 patent/US20210323997A1/en not_active Abandoned
-
2022
- 2022-12-16 US US18/083,037 patent/US20230295220A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43960B1 (fr) | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 | |
| MA34909B1 (fr) | Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih | |
| JOP20220267A1 (ar) | مركبات أمينو ثيازول تحمل بدائل بصفتها مثبطات لـثنائي أسيل غليسرول كيناز زيتا لتنشيط المناعة | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA39985B1 (fr) | 1h-pyrrolo [2,3-c]pyridine -7(6h)-ones et pyrazolo[3,4-c]pyridine-7(6h)-ones en tant qu'inhibiteurs de protéines bet | |
| MA34400B1 (fr) | Dérivés d'acide 2-quinolinyl-acétique en tant que composés antiviraux contre le vih | |
| MA39317A1 (fr) | Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe | |
| MA40886B1 (fr) | Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih | |
| MA44674B1 (fr) | Inhibiteurs de bromodomaine | |
| MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
| MA38483A1 (fr) | Inhibiteurs de l'ido | |
| WO2019035864A8 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins | |
| MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA34170B1 (fr) | Inhibiteurs de transcriptase inverse non nucléosidiques | |
| MA38182A1 (fr) | Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih) | |
| EA202192433A1 (ru) | Соединения, полезные в терапии вич | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MA39374A1 (fr) | Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle | |
| MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA41185B1 (fr) | Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| MA40149A1 (fr) | Dérivés de nucléoside 4'-vinyle substitués utiles en tant qu'inhibiteurs de la réplication due l'arn du virus respiratoire syncytial | |
| MA38678A1 (fr) | Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués | |
| MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
| MA46563B1 (fr) | Compositions dispersibles |